Doctors have developed
an injection that eradicated entire tumours in patients with
treatment-resistant cancers during a clinical trial, offering new hope for
thousands of people with limited treatment options.
The injection,
known as amivantamab, shrank tumours in 42 per cent of patients with recurrent
and metastatic head and neck cancer, according to an international study led by
the Institute of Cancer Research (ICR), London.
Researchers administered amivantamab to patients whose cancer had stopped responding to standard treatments, including immunotherapy and platinum-based






